President & CEO of NGT BioPharma Consultants, Dr. O’Brien is recognized as a forward-thinking, technology-centric business executive with over 25 years of biopharmaceutical industry research and development experience.
Dr. O’Brien served as the AVP of Wyeth’s Synthesis Research & Development (SR&D) group from 2001 through 2009 and as the acting head of Chemical Development in 2008. In 2010 Dr. O’Brien transitioned to Pfizer as Pharmaceutical Sciences Vice President of Technology & Innovation, overseeing a group focused on the creation and management of multi-party external alliances directed towards the design, development, and implementation of high-value technology platforms. In this role, he championed the design, fabrication, and implementation of a portable, continuous, miniature, and modular (PCMM) solid oral dose manufacturing facility. The first of its kind facility was fabricated off-site, assembled in a Pfizer warehouse, and ultimately commissioned to provide launch and commercial supplies of the 2019 FDA approved oncology drug Daurismo.
After leaving Pfizer in 2018, Dr. O’Brien established multi-disciplinary consulting firm, NGT BioPharma Consultants, to partner with life sciences companies of all sizes, offering strategic advice, ‘boots on the ground’ assistance, and outsourcing solutions in the areas of biopharmaceutical drug development and the advanced technologies foundational to the industry’s development & manufacturing of medicines.
Over the years, Dr. O’Brien has received many awards and recognitions, including Case Western Reserve University’s prestigious 2017 Department of Chemistry Outstanding Alumnus Award and being named an Industry Influencer on The Medicine Maker 2019 Power List. His contributions to the public domain include more than 60 publications, presentations, and patents.
